source
- Revolution Medicines' daraxonrasib nearly doubles survival in pancreatic cancer trialData presented at the American Society of Clinical Oncology meeting showed that Revolution Medicines' experimental drug daraxonrasib significantly extended survival for patients with metastatic pan…
- Ivonescimab cuts death risk by one-third in Chinese lung cancer trial, adds four-month survivalA trial in China evaluated ivonescimab combined with chemotherapy in patients newly diagnosed with advanced non-small cell lung cancer. The study was presented at the American Society of Clinical O…